NeogenTC Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Investors
-
17
NeogenTC General Information
Description
Developer of cancer therapies designed to provide personalized anticancer treatment. The company offers engineered tumor-infiltrating lymphocyte therapies, T cell receptor-modified T cell development, and scientific research capabilities to administer cell therapy that can target solid cancers that are difficult to treat, enabling patients with cancer and the medical research community to access personalized immunotherapy that harnesses the body's immune system to target cancer cells and advance treatment options.
Contact Information
Website
www.neogentc.comCorporate Office
- 11th floor, 88 Olympic-ro 43-gil
- Pungnap-dong, Asan Institute for Life Sciences Convergence Research Center, Songpa-gu
- Seoul
- South Korea
Corporate Office
- 11th floor, 88 Olympic-ro 43-gil
- Pungnap-dong, Asan Institute for Life Sciences Convergence Research Center, Songpa-gu
- Seoul
- South Korea
NeogenTC Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 01-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 27-May-2024 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 05-Apr-2021 | $13.2M | $13.7M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 21-Dec-2020 | $455K | $455K | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NeogenTC Patents
NeogenTC Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026506548-A | Highly active transposase protein for transposon systems and its uses | Pending | 02-Feb-2023 | ||
| EP-4663752-A1 | Highly active transposase protein of transposon system, and use thereof | Pending | 02-Feb-2023 | ||
| EP-4663752-A4 | Highly active transposase protein of transposon system, and use thereof | Pending | 02-Feb-2023 | ||
| WO-2024162830-A1 | Highly active transposase protein of transposon system, and use thereof | Inactive | 02-Feb-2023 | ||
| WO-2024151001-A1 | Method and device for generating immunogenicity information using artificial intelligence technology | Inactive | 09-Jan-2023 | G16B40/20 |
NeogenTC Signals
NeogenTC Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| S&S Investment | Venture Capital | Minority | ||
| Arche Investment | Corporate Venture Capital | Minority | ||
| Bluepoint | Venture Capital | Minority | ||
| Cosine Investment | Venture Capital | Minority | ||
| Devsisters Ventures | Corporate Venture Capital | Minority |
NeogenTC FAQs
-
When was NeogenTC founded?
NeogenTC was founded in 2020.
-
Where is NeogenTC headquartered?
NeogenTC is headquartered in Seoul, South Korea.
-
What is the size of NeogenTC?
NeogenTC has 9 total employees.
-
What industry is NeogenTC in?
NeogenTC’s primary industry is Drug Discovery.
-
Is NeogenTC a private or public company?
NeogenTC is a Private company.
-
What is NeogenTC’s current revenue?
The current revenue for NeogenTC is .
-
How much funding has NeogenTC raised over time?
NeogenTC has raised $13.7M.
-
Who are NeogenTC’s investors?
S&S Investment, Arche Investment, Bluepoint, Cosine Investment, and Devsisters Ventures are 5 of 17 investors who have invested in NeogenTC.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process